Cargando…

Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma

BACKGROUND: We aimed to determine whether plasma cell-free DNA (cfDNA) concentration is associated with survival in patients with isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM). METHODS: Pre-operative and post-chemoradiotherapy blood samples were prospectively collected from patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bagley, Stephen J, Till, Jacob, Abdalla, Aseel, Sangha, Hareena K, Yee, Stephanie S, Freedman, Jake, Black, Taylor A, Hussain, Jasmin, Binder, Zev A, Brem, Steven, Desai, Arati S, O’Rourke, Donald M, Long, Qi, Nabavizadeh, Seyed Ali, Carpenter, Erica L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883768/ https://www.ncbi.nlm.nih.gov/pubmed/33615225 http://dx.doi.org/10.1093/noajnl/vdab011

Ejemplares similares

Imaging and histopathologic correlates of plasma cell-free DNA concentration and circulating tumor DNA in adult patients with newly diagnosed glioblastoma
por: Nabavizadeh, Seyed Ali, et al.
Publicado: (2020)

2137 Percentage of viable tumor Versus radiation treatment effect in surgical specimens is not associated with outcomes in recurrent glioblastoma
por: Schwab, Robert D., et al.
Publicado: (2018)

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)

(18)F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling
por: Henderson, Fraser, et al.
Publicado: (2020)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Arterial Spin Labeling and Dynamic Susceptibility Contrast-enhanced MR Imaging for evaluation of arteriovenous shunting and tumor hypoxia in glioblastoma
por: Nabavizadeh, S. Ali, et al.
Publicado: (2019)

Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging
por: Akbari, Hamed, et al.
Publicado: (2021)

Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma
por: Nasrallah, MacLean P., et al.
Publicado: (2019)

Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma
por: Durgin, Joseph S., et al.
Publicado: (2021)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1
por: Rathore, Saima, et al.
Publicado: (2018)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas
por: de Godoy, Laiz Laura, et al.
Publicado: (2023)

Three‐dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma
por: Verma, Gaurav, et al.
Publicado: (2018)

Updates in IDH-Wildtype Glioblastoma
por: Melhem, Jawad M., et al.
Publicado: (2022)

The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomics
por: Bakas, Spyridon, et al.
Publicado: (2022)

Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma
por: Fathi Kazerooni, Anahita, et al.
Publicado: (2022)

GEN-10 WHOLE GENOME LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE
por: Nakashima, Takuma, et al.
Publicado: (2022)

Implications of Cellular Immaturity in Necrosis and Microvascularization in Glioblastomas IDH-Wild-Type
por: Orasanu, Cristian Ionut, et al.
Publicado: (2022)

Molecular landscape of IDH ‐wild type, pTERT ‐wild type adult glioblastomas
por: Liu, Emma Munan, et al.
Publicado: (2022)

Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma
por: Wang, Sumei, et al.
Publicado: (2018)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
por: van Noorden, Cornelis J.F., et al.
Publicado: (2021)

Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma
por: Mohan, Suyash, et al.
Publicado: (2021)

Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
por: Poon, Candice C., et al.
Publicado: (2019)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients
por: Kasper, Johannes, et al.
Publicado: (2021)

Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma
por: Cao, Wenjun, et al.
Publicado: (2023)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response
por: Tang, Oliver Y., et al.
Publicado: (2022)

Maternal-Cord Blood Vitamin D Correlations Vary by Maternal Levels
por: Wegienka, Ganesa, et al.
Publicado: (2016)

Factors Associated with Increased Survival after Surgical Resection of Glioblastoma in Octogenarians
por: Abdullah, Kalil G., et al.
Publicado: (2015)

Whole genome duplication is an early event leading to aneuploidy in IDH-wild type glioblastoma
por: Boisselier, Blandine, et al.
Publicado: (2018)

Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma
por: Galijašević, Malik, et al.
Publicado: (2021)

The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma
por: Kaye, Brandon, et al.
Publicado: (2023)

MYEF2: an immune infiltration-related prognostic factor in IDH-wild-type glioblastoma
por: Zhang, Yunxiao, et al.
Publicado: (2023)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

IDH1 mutations in a Brazilian series of Glioblastoma
por: Uno, Miyuki, et al.
Publicado: (2011)

Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond
por: El Khayari, Abdellatif, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jpsia54ts60ohkm7ua4f80t44s